News · 26 weeks10%
2025-12-072026-05-31
Mix090d
No activity.
Latest news
25 items- NEWSGPOPlus+ to Present at the Sequire Investor Summit on January 20th - 22nd in San Juan, Puerto RicoCEO Brett H. Pojunis to highlight key milestones and growth strategy, including AI-powered distribution, significant increase in revenue, and margin gains, to investors.LAS VEGAS, NV / ACCESS Newswire / January 9, 2026 / GPO Plus, Inc.(OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model, is pleased to announce it will be presenting at the upcoming Sequire Investor Summit 2026.The Sequire Investor SummitReturning for its fourth highly anticipated edition, the Sequire Investor Summit takes place at the prestigious Condado Vanderbilt Hotel in San Juan, Puerto Rico. Host
- SECSEC Form 10-Q filed by SRAX Inc.10-Q - SRAX, Inc. (0001538217) (Filer)
- SECSEC Form 10-Q filed by SRAX Inc.10-Q - SRAX, Inc. (0001538217) (Filer)
- SECSEC Form 10-K filed by SRAX Inc.10-K - SRAX, Inc. (0001538217) (Filer)
- FDAJune 7, 2024 - FDA Roundup: June 7, 2024For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
- SECSEC Form 8-K filed by SRAX Inc.8-K - SRAX, Inc. (0001538217) (Filer)
- PRSRAX Signs Agreement to Merge with DNA HoldingsWestlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, announced today it has entered into a definitive merger agreement with DNA Holdings Venture Inc. pursuant to which the shareholders of DNA will become the majority owners of SRAX's outstanding common stock as more fully described below upon the closing of the merger. DNA has been a long term investor in SRAX and currently owns approximately 35% of the company. DNA is a Web3 investment company which provides both advisory services and invests in Web3 infrastructure. The company was foun
- SECSRAX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- SECSRAX Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- FDAMarch 22, 2024 - FDA Roundup: March 22, 2024For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). Pemgarda is
- SECSRAX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- PRSRAX SELECTS XDEFI AS WEB3 WALLET PARTNER, ENABLING SECURE ACCESS TO DIGITAL ASSETS FOR ACTIVE EQUITY INVESTORSLos Angeles, March 05, 2024 (GLOBE NEWSWIRE) -- Los Angeles, [5 March 2024] - SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, today announced it has selected XDEFI as its Web3 wallet partner. XDEFI is a pioneering multichain cryptocurrency wallet. The partnership will enable SRAX's network of active equity investors to access decentralized applications and assets spanning 200+ blockchains, seamlessly and securely. In addition, SRAX clients who download the wallet will be eligible for airdrops in $XDEFI tokens and many future token airdrops. In 2023, over $5 billion was given away through
- 13D/GSEC Form SC 13G/A filed by SRAX Inc. (Amendment)SC 13G/A - SRAX, Inc. (0001538217) (Subject)
- 13D/GSEC Form SC 13G/A filed by SRAX Inc. (Amendment)SC 13G/A - SRAX, Inc. (0001538217) (Subject)
- NEWS$1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively BuyingThe Dow Jones index closed higher by over 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. SRAX The Trade: SRAX, Inc. (OTC:SRAX) CEO Christopher Miglino acquired a total of 15,000 shares an average price of $0.05. To acquire these shares, it cost around $750. What’s Happening: The company’s stock dipped 77% over the past month. What
- INSIDERMiglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)4 - SRAX, Inc. (0001538217) (Issuer)
- PRSRAX SHAREHOLDER LETTERWestlake Village, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, As I write to you today, I do so with a sense of deep reflection on the year that has passed. It's been a period that tested our resilience. I want to express my sincere regret for the concerns and frustrations you may have experienced as a result of our stock price. Addressing Our Challenges Head-On Our delisting from the NASDAQ market was a moment for serious introspection. Looking back, there were areas where we should have been more proactive, especially as it relates to our accounting team's leadership and the complexities of the accounting for our business. Bringing in new experts was a turning point for th
- FDANovember 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting DisorderFor Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains
- SECSRAX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- SECSEC Form 10-Q filed by SRAX Inc.10-Q - SRAX, Inc. (0001538217) (Filer)
- SECSRAX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- SECSRAX Inc. filed SEC Form 8-K: Leadership Update8-K - SRAX, Inc. (0001538217) (Filer)
- SECSEC Form 10-Q filed by SRAX Inc.10-Q - SRAX, Inc. (0001538217) (Filer)
- SECSRAX Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - SRAX, Inc. (0001538217) (Filer)
- PRSRAX Creates Advisory Board With Company's Largest ShareholdersLOS ANGELES, July 17, 2023 (GLOBE NEWSWIRE) -- SRAX, Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, announced today it has created an Advisory Board that is comprised of 4 of the company's largest shareholders. "SRAX has some amazing investors and we want to create a formal relationship with some of them so they can share their insights as we navigate getting our fillings back in order and restructure the business. These advisors are all very invested in the business, owning millions of shares collectively, and they all have a diverse background as it relates to small cap companies" Said Ch
SRAX FAQ
5 questionsWhat does SRAX Inc. do?
SRAX, Inc., a technology company, focused on enhancing communications between public companies and their shareholders and investors in the United States. The company offers Sequire, a Saas platform that allows issuers to track their shareholders' behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels. It also organizes and hosts investor conferences within the micro and small- cap space. The company markets and sells its services through its in-house sales and marketing team. The company was formerly known as Social Reality, Inc. and changed...Where does SRAX stock trade?
SRAX Inc. (SRAX) is listed on NASDAQ.What sector and industry is SRAX in?
SRAX Inc. operates in the Consumer Discretionary sector, Advertising industry.What companies are similar to SRAX?
Notable peers in the same industry include OMC (Omnicom Group Inc.), IPG (Interpublic Group of Companies Inc.), WPP (WPP plc), STGW (Stagwell Inc.), CCO (Clear Channel Outdoor Holdings Inc.). Compare SRAX side-by-side with any of them on Quantisnow.How can I track SRAX on Quantisnow?
Quantisnow aggregates SRAX Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRAX to receive live email and push alerts on every new disclosure.